1039359-46-0

Basic information

• Product Name: (+)-4-(2-methylphenyl)-1-{(7R)-5,6,7,8-tetrahydrospiro[cyclohepta[b]pyridine-9,2'-[1,3]dioxolan]-7-ylmethyl}piperidine
• Synonyms: (+)-4-(2-methylphenyl)-1-{(7R)-5,6,7,8-tetrahydrospiro[cyclohepta[b]pyridine-9,2'-[1,3]dioxolan]-7-ylmethyl}piperidine
• CAS NO: 1039359-46-0
• Molecular Weight: 392.541
• Mol File: 1039359-46-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (+)-4-(2-methylphenyl)-1-{(7R)-5,6,7,8-tetrahydrospiro[cyclohepta[b]pyridine-9,2'-[1,3]dioxolan]-7-ylmethyl}piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-4-(2-methylphenyl)-1-{(7R)-5,6,7,8-tetrahydrospiro[cyclohepta[b]pyridine-9,2'-[1,3]dioxolan]-7-ylmethyl}piperidine(1039359-46-0)
• EPA Substance Registry System: (+)-4-(2-methylphenyl)-1-{(7R)-5,6,7,8-tetrahydrospiro[cyclohepta[b]pyridine-9,2'-[1,3]dioxolan]-7-ylmethyl}piperidine(1039359-46-0)

Safety Data

• Hazardous Substances Data: 1039359-46-0(Hazardous Substances Data)

Upstream product

• 82212-02-0 4-(2-methylphenyl)piperidine hydrogen chloride salt 
• 1039359-02-8 (+)-5,6,7,8-tetrahydrospiro[cyclohepta[b]pyridine-9,2'-[1,3]dioxolan]-7-ylmethyl 4-methylbenzenesulfonate 

Downstream Products

• 1039359-38-0 (-)-4-(2-methylphenyl)-1-{(7R)-[9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl]methyl}piperidine 

Relevant articles and documents

A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K + channel

A series of compounds based on 7-{[4-(2-methylphenyl)piperidin-1-yl]methyl} -6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol ((-)-8b), a potent and selective opioid receptor-like 1 (ORL1) antagonist, was prepared and evaluated using structure-activity relationship studies with the aim of removing its affinity to human ether-a-go-go related gene (hERG) K+ channel. From these studies, 101 was identified as an optimized structure with respect to ORL1 antagonist activity, and affinity to the hERG K+channel. Furthermore, 101 showed good in vivo antagonism with a wide therapeutic index in regards to adverse cardiovascular effects.